Observational Study of Guselkumab Treatment Persistence in Adults with Moderate-to-Severe Plaque Psoriasis in Romania

What This Trial Is About

Researchers are evaluating how many people with moderate-to-severe plaque psoriasis continue treatment with guselkumab over a period of two years. This observational study focuses on patients in Romania who have not received biological treatments before and are starting guselkumab as part of their routine medical care. The study aims to understand treatment persistence and patient outcomes with this medication. Participants include those diagnosed with moderate-to-severe plaque psoriasis who have never been treated with biological therapies and are prescribed guselkumab according to standard care. The study collects data from participants medical records without altering their treatment plan or requiring additional interventions. No new treatments are provided by the study it simply observes and records routine clinical practice. During the study, researchers will review medical records and assess various outcomes such as time until treatment discontinuation, skin improvement scores using PASI and IGA scales, quality of life measures, and safety through adverse event reports. Data will be gathered at multiple time points up to two years. Participants baseline characteristics like age, gender, height, weight, disease severity, smoking history, and alcohol use will also be recorded. The study is led by Janssen Research & Development, LLC and will run until late 2028.

A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania